Reimbursement and value-based pricing: Stratified cost-effectiveness analysis may not be the last word

Health Economics

Volumn 20, Issue 6, 2011, Pages 688-698

  Hawkins, Neil ^a   Scott, David A ^a  

^a ICON PLC   (United Kingdom)

Author keywords

Stratified cost effectiveness analysis; Value based pricing

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE SYSTEM; OUTCOME ASSESSMENT; POPULATION SIZE; PRIORITY JOURNAL; REIMBURSEMENT;

ADULT; AGED; COST-BENEFIT ANALYSIS; FEES AND CHARGES; GREAT BRITAIN; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MIDDLE AGED; MODELS, STATISTICAL; QUALITY OF HEALTH CARE; REIMBURSEMENT MECHANISMS; RESOURCE ALLOCATION;

EID: 79953731978     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1625     Document Type: Article

References (32)

1. The Association of the British Pharmaceutical Industry and the Department of Health. 2008. The Pharmaceutical Price Regulation Scheme 2009. Department of Health: London.
2. Barham L, Mansell P. 2009. Assessing NICE's expanding role. PharmaTimes, 27-29 April.
3. Bowley A. 1928. Bilateral monopoly. The Economic Journal 38: 651-659.
4. Buxton M. 2007. Looking for willingness-to-pay (WTP) threshold for a QALY - does it make sense? a practical view. ISPOR Connections, 15 August 9-11.
5. Claxton K. 2007. OFT, VBP: QED? Health Economics 16(6): 545-558.
6. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. 2008. Value based pricing for NHS drugs: an opportunity not to be missed? British Medical Journal 336(7638): 251-254.
7. Coyle D, Buxton M, O'Brien B. 2002. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Economics 12(5): 421-427. (Pubitemid 36603553)
8. Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J. 2007. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. Journal of Health Services Research and Policy 12(1): 56-58. (Pubitemid 46174208)
9. Danzon PM. 1998. The economics of parallel trade. Pharmacoeconomics 13: 293-304. (Pubitemid 28123369)
10. Danzon PM, Ketcham JD. 2004. Reference pricing of pharmaceuticals: evidence from Germany, the Netherlands and New Zealand. Frontiers in Health Policy Research 7: 1-54.
11. Danzon PM, Towse A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics 3: 183-205.
12. Dowie J. 2004. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Economics 13: 453-459. (Pubitemid 38660394)
13. Garattini L, Cornago D, Compadri PD. 2007. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 82(3): 330-339.
14. Hoyle M. 2008. Future drug prices and cost-effectiveness analysis. Pharmacoeconomics 26(7): 589-602. (Pubitemid 351871554)
15. Kyle MK, Allsbrook JS, Schulman KA. 2008. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union. Health Services Research 43: 1308-1324.
16. Lansley A. 2008. Nice doesn't have to be nasty. Daily Telegraph, 10 September.
17. Mark D, Hlatky M, Califf R, Naylor C, Lee K, Armstrong P, Barbash G, White H, Simoons ML, Nelson CL. 1995. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 332: 1418-1424.
18. McCabe C, Claxton K, Culyer AJ. 2008. The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics 26(9): 733-744.
19. Nash J. 1950. The bargaining problem. Econometrica 18: 155-162.
20. National Institute for Health and Clinical Excellence. 2008. Final Appraisal Determination - Erlotinib for the Treatment of Non-small-cell Lung Cancer. NICE: London, September.
21. National Institute for Health and Clinical Excellence. 2009. Appraising Life-extending, End of Life Treatments. NICE: London, January.
22. Neumann P. 2005. Using Cost-effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford University Press: Oxford.
23. O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. 2002. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Economics 11: 175-180.
24. Office of Fair Trading. 2007. The pharmaceutical price regulation scheme. An OFT market study. Technical Report, Office of Fair Trading, London, UK.
25. Pollack A. 2007. Pricing pills by the results. New York Times, 14 July.
26. Schneeweiss S. 2007. Reference drug programs: effectiveness and policy implications. Health Policy 81: 17-28. (Pubitemid 46329760)
27. Stinnett A, Mullahy J. 1998. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analyses. Medical Decision Making 18: S68-S80. (Pubitemid 28175944)
28. Thornton S. 2007. Drug price reform in the UK: debunking the myths. Health Economics 16(10): 981-992. (Pubitemid 47534728)
29. Towse A. 2007. If it ain't broke, don't price fix it: the OFT and the PPRS. Health Economics 16(7): 653-665. (Pubitemid 47090935)
30. Waugh N, Scott DA. 1998. How should different life expectancies be valued? British Medical Journal 316: 1316.
31. Webb DJ, Walker A. 2007. Value-based pricing of drugs in the UK. Lancet 369: 1415-1416. (Pubitemid 46635766)
32. Wind K. 2008. Risk sharing schemes - improving patient access to new drugs. Hospital Pharmacist 15: 114. (Pubitemid 351520835)